3D Markers Shaping the Future
BioZorb® 3D Bioabsorbable Marker
BioZorb® is a three-dimensional (3D) implantable marker that consists of a spiral, bioabsorbable framework embedded with 6 permanent, titanium clips designed to precisely mark your surgical excision site. Designed to improve outcomes in Breast Conserving Surgery and be absorbed into the body over several years.
BioZorb® facilitates 3-dimensional radiation therapy targeting and comes in a range of sizes from 2-5cm including three Lower Profile (LP) designs. Available in Low Profile (LP) designed for smaller, flatter surgical cavities.
Visualise the difference
- Cosmetic results: BioZorb® has been shown to yield good/excellent cosmetic outcomes for at least 2 years post-surgery1
- Radiation: 96% of radiation oncologists reported “improved accuracy” in setup & boost targeting in a prospective registry study comprising 337 patients2
- Mammography: S et al (2015), have demonstrated minimal scarring after breast conservation therapy when using BioZorb® to mark the site3
- Radiation oncologists perceived they had “improved accuracy” in follow-up medical procedure, suggesting increased confidence through the use of BioZorb® marker2
- In 92% of cases radiation oncologists verified as “easily seen” on CT2
- In 90% of patients, physicians have rated comesis good/excellent2
Permanent surgical site marking
BioZorb®: Not CE marked. Not available for sale. Not for distribution.
- Kaufman CS, et al. Long Term Value of 3-D Bioabsorbable Tissue Marker on Radiation Planning & Targeting, Cosmesis and Follow-up Imaging. Poster presented at the American Society of Breast Surgeons 17th Annual Meeting, April 27 – 30, 2017.
- Kaufman CS, et al. Registry Study of 337 Bio-Absorbable 3-D Implants Marking Lumpectomy Cavity Benefit Cosmesis While Targeting Radiation. Poster presented at the Society of Surgical Oncology Annual Cancer Conference March 15-17, 2017.
- Single site prospective Harms S, et al. Mammographic imaging after partial breast reconstruction: Impact of a bioabsorbable breast implant. J Clin Oncol 33, 2015 (suppl 28S; abstr 111).